Drug Profile
EWA 401
Alternative Names: EW-A-401; VEGF ZFP +434; VZ+434-P65; ZFP-Therapeutics; Zinc finger DNA binding protein - SangamoLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Sangamo BioSciences
- Class Gene therapies; Vascular disorder therapies; Zinc finger DNA binding proteins
- Mechanism of Action Gene transference; Vascular endothelial growth factor A expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Intermittent claudication; Ischaemic heart disorders; Peripheral vascular disorders